to be supported by the evidence, collected during the past few years, that sympathetic neural outflow is almost completely withdrawn during a neurally mediated syncopal episode. 2 -7 There are, however, two features of the neuroadrenergic responses to syncope that deserve to be highlighted. The first refers to the evidence that, despite the almost complete disappearance of the sympathetic neural discharge (so-called 'neural silence') reported during syncope, plasma norepinephrine and epinephrine concentrations, i.e. the adrenergic neurotransmitters, are only partially reduced in the blood reservoir. 8, 9 This implies that the hypothesis that neurogenic syncope might depend on an almost complete withdrawal of the neural adrenergic outflow to the circulation is not supported by the behaviour of the biochemical markers of adrenergic function. The second feature refers to the temporal patterns of the neural changes immediately preceding and accompanying vasovagal syncope. Indeed, there is evidence from previous studies that syncope-related sympathetic inhibition (indeed this was what previous studies have almost univocally reported) is preceded immediately before its appearance by a marked sympathetic activation, which parallels the decline in blood pressure triggered by the fainting episode. 2, 3 Only in a later stage of the syncope does the sympathetic inhibition reported by previous studies take place. How does the persistence of a normal sympathetic nerve firing pattern during syncope shown by Vaddadi and co-workers 1 reconcile with the 'neural silence' observed in previous reports? 2 -7 The authors have done their best in the Discussion to provide a sound answer to the above question. I would underline, as likely explanations, however, the following not mutually exclusive hypotheses. First, in many of the previous studies the reported 'neural silence' might have been in some way related to methodological problems, i.e. the loss of the sympathetic traffic signal during the syncope. This was not the case, however, in the report of Vaddadi et al., 1 in which in 10 out of the 16 patients examined the nerve recording site was fully maintained, allowing the persistence of a normal sympathetic activity during syncope to be shown. Secondly, the fact that in the study of Vaddadi et al. the recruited patients had a clinical history of vasovagal syncope, at variance from other studies, 2 -7 allows the hypothesis to be advanced that the sympathetic neural responses to a fainting episode may be different according to the clinical history of recurrent vasovagal syncopes. This implies that the 'neuroadrenergic profile' of people suffering from vasovagal syncope may not necessarily be homogeneous and that factors such as the genetic background may be important for triggering such heterogeneous behaviour. In commenting on the results of the report by Vaddadi and coworkers, 1 two other considerations should be taken into account.
The first refers to the fact that the behaviour of sympathetic nerve traffic in the skeletal muscle area does not necessarily reflect the one seen in other districts. This has been shown, for example, in human obesity and in relation to the ageing process, in which some neural areas (the heart and the skin) do not display the same quantitative profile (sympathetic activation) reported in the muscle vascular area. 10, 11 The second consideration refers to the behaviour of the arterial baroreflex function in subjects with neurogenic syndrome. In the report of Vaddadi et al., 1 baroreflex modulation of vagal drive to the sinus node, as assessed via the so-called 'sequence' method, appears to be impaired, as compared with what was found in a group of healthy controls. This does not necessarily mean, however, that the baroreflex dysfunction in modulating heart rate should also apply to baroreceptor control of peripheral sympathetic neural outflow. However, evidence provided by Bèchir and co-workers 7 conclusively shows that baroreceptor modulation of sympathetic outflow during the vasovagal episode is somewhat impaired, similarly to that reported for baroreflex heart rate control. Such a reflex alteration is not in contrast to the preservation of the sympathetic neural activity observed during the fainting episode and reported in the study of Vaddadi et al. This is because there might be several factors participating in guaranteeing a normal sympathetic function during vasovagal syncope. This may be the case for metabolic factors, such as hyperinsulinaemia. 12 This may also be the case for the renin-angiotensin activation occurring during syncope.
12
A second study on syncope has also been published recently, reporting the follow-up of the Evaluation of Guidelines in Syncope Study 2 (EGIS 2). 13 The main study aim was to define the shortand long-term prognosis of patients referred to an emergency ward for syncope. The death rate was higher (17% of all deaths) in the first month of observation, while reoccurrence of the syncopal episode was low overall in both the short and the long term (0.3% and 0.8% in the first month and in the second year, respectively). Mortality was higher in patients with a clinical history of a previous cardiovascular disease or in those displaying electrocardiographic abnormalities. Both of these two factors represent the main predictors of short-or long-term mortality on multivariate analysis. 13 The study results therefore reinforce the concept that particular attention should be paid in the emergency room to patients with syncope and at high risk of fatal complications, for which hospitalization for further investigations should be highly recommended.
What is the common link between the two studies which should be regarded as the 'take home message' for the readership of the journal? There may be several, but I would like to underline that the major link could be the renaisssance of interest in syncope, which at present is regarded as an 'independent disease' with a complex pathophysiological background but also with a welldefined prognostic impact.
14 Whether the different therapeutic approaches available for syncope carry a different prognostic impact remains to be seen. This implies that the scientific and clinical interest in this disease will continue during the coming years.
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